GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arctic Bioscience AS (OSL:ABS) » Definitions » Minority Interest

Arctic Bioscience AS (OSL:ABS) Minority Interest : kr0.00 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Arctic Bioscience AS Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Arctic Bioscience AS's minority interest for the quarter that ended in Jun. 2024 was kr0.00 Mil.


Arctic Bioscience AS Minority Interest Historical Data

The historical data trend for Arctic Bioscience AS's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arctic Bioscience AS Minority Interest Chart

Arctic Bioscience AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Minority Interest
Get a 7-Day Free Trial - - - - -

Arctic Bioscience AS Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Arctic Bioscience AS Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.


Arctic Bioscience AS Business Description

Traded in Other Exchanges
N/A
Address
Industrivegen 42, Orsta, NOR, 6155
Arctic Bioscience AS is a Norwegian biotechnology company. The company is focused on developing products and solutions based on bioactive marine compounds. The product portfolio includes nutraceuticals and pharmaceuticals. It is currently developing a novel, cost-efficient oral treatment (HRO350) for mild-to-moderate psoriasis. Its nutraceutical products are sold globally to both B2C and B2B under the Romega brand. The company operates in Norway, Europe, Australia and APAC.

Arctic Bioscience AS Headlines

No Headlines